查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1465588

連續生物加工市場規模 - 按產品[儀器、消耗品]、營運規模、製程、應用、最終用戶和全球預測 2024 - 2032

Continuous Bioprocessing Market Size - By Product [Instruments, Consumables], Scale of Operation, Process, Application, End-user & Global Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 230 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

在該領域領先公司的進步和成就的推動下，2024 年至 2032 年間，全球連續生物加工市場的複合年成長率將超過 22.1%。隨著公司不斷創新和開發新技術，生物加工產業正在經歷向連續製造方法的轉變。例如，2023年11月，全球知名合約研究、開發和製造組織（CRDMO）藥明生物揭露了利用WuXiUPTM實現端到端DS中試生產的成果。這種具有超高生產率的專有連續生物加工平台在其非 GMP 試點工廠實施。

這些進步包括整合和自動化系統的開發、一次性技術以及改進的監控和控制策略。領先公司在製程效率、產品品質和可擴展性方面取得了顯著的里程碑，推動了連續生物製程在各種生物製藥應用中的採用。此外，連續生物加工還具有降低成本、提高生產力和加快上市時間等優勢，進一步刺激了市場需求。隨著該行業接受這些創新，連續生物加工市場預計將在未來幾年實現大幅成長和擴張。

整個連續生物加工產業根據產品、經營規模、製程、應用、最終用戶和地區進行分類。

耗材領域將在2024年至2032年經歷嚴格的發展。 。這些消耗品在實現高效且可擴展的連續生物加工操作方面發揮著至關重要的作用。此外，與傳統不銹鋼設備相比，它們還具有降低交叉污染風險、更快的周轉時間和更低的營運成本等優勢。隨著全球生物製藥生產能力的不斷擴大，連續生物加工市場對耗材的需求將持續穩定成長。

從2024 年到2032 年，研發領域的連續生物加工市場佔有率將實現顯著的複合年成長率。和更快的開發時間表。隨著生物製藥公司尋求簡化其研發工作並加快新療法的上市時間，連續生物加工的採用正在迅速獲得關注。它能夠促進連續資料生成、流程最佳化以及從小規模實驗到商業生產的放大，使其成為現代生物製藥研發工作中不可或缺的工具。因此，連續生物加工可望重塑生物製藥創新和發展的格局。

亞太連續生物加工市場從 2024 年到 2032 年將呈現出值得稱讚的複合年成長率。此外，不斷增加的研發投資以及政府促進生物技術的措施正在推動市場成長。亞太地區作為藥品和生物製劑製造中心的戰略重要性進一步推動了對連續生物加工解決方案的需求。因此，亞太市場正成為連續生物加工市場全球擴張的重要貢獻者。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 對生物製藥的需求不斷增加
      • CMO 和 CDMO 擴大採用連續生物程序
      • 連續生物加工技術的進步
    • 產業陷阱與挑戰
      • 設備成本高
      • 嚴格的監管要求
  • 成長潛力分析
  • 監管環境
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按產品分類，2018 年 - 2032 年

  • 主要趨勢
  • 儀器
    • 色譜系統
    • 過濾系統和裝置
    • 生物反應器
    • 其他儀器
  • 耗材
    • 細胞培養基和緩衝液
    • 試劑

第 6 章：市場估計與預測：按營運規模分類，2018 年 - 2032 年

  • 主要趨勢
  • 商業的
  • 研究與開發

第 7 章：市場估計與預測：按流程分類，2018 年 - 2032 年

  • 主要趨勢
  • 下游生物過程
  • 上游生物程序

第 8 章：市場估計與預測：按應用分類，2018 年 - 2032 年

  • 主要趨勢
  • 單株抗體
  • 疫苗
  • 細胞和基因治療
  • 其他應用

第 9 章：市場估計與預測：按最終用戶分類，2018 年 - 2032 年

  • 主要趨勢
  • 製藥和生物技術公司
  • CMO 和 CRO
  • 研究和學術機構

第 10 章：市場估計與預測：按地區，2018 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 中東和非洲其他地區

第 11 章：公司簡介

  • 3M Company
  • Bionet
  • Danaher Corporation (Pall Corporation)
  • Eppendorf SE
  • FUJIFILM HOLDINGS CORPORATION
  • Merck KGaA
  • Repligen Corporation
  • Sartorius AG
  • Thermo Fisher Scientific Inc.
  • WuXi Biologics
簡介目錄
Product Code: 8350

Global Continuous Bioprocessing Market will witness over 22.1% CAGR between 2024 and 2032, propelled by advancements and achievements from leading companies in the field. As companies continue to innovate and develop novel technologies, the bioprocessing industry is experiencing a transformation towards continuous manufacturing methods. For instance, in November 2023, WuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), disclosed the achievement of end-to-end DS manufacturing at a pilot scale, utilizing WuXiUPTM. This proprietary continuous bioprocessing platform with ultra-high productivity was implemented at its non-GMP pilot plant.

These advancements include the development of integrated and automated systems, single-use technologies, and improved monitoring and control strategies. Leading companies are achieving remarkable milestones in process efficiency, product quality, and scalability, driving the adoption of continuous bioprocessing across various biopharmaceutical applications. Moreover, continuous bioprocessing offers advantages such as reduced costs, increased productivity, and faster time-to-market, further fueling market demand. As the industry embraces these innovations, the Continuous Bioprocessing Market is poised for substantial growth and expansion in the coming years.

The overall Continuous Bioprocessing Industry is classified based on the product, scale of operation, process, application, end-user, and region.

The consumables segment will undergo rigorous development from 2024 to 2032. As the biopharmaceutical industry increasingly adopts continuous manufacturing methods, the demand for consumables such as single-use bioreactors, filtration systems, chromatography columns, and sensors is on the rise. These consumables play a crucial role in enabling efficient and scalable continuous bioprocessing operations. Moreover, they offer advantages such as reduced risk of cross-contamination, faster turnaround times, and lower operating costs compared to traditional stainless-steel equipment. With the continuous expansion of biopharmaceutical manufacturing capacities worldwide, the demand for consumables in the Continuous Bioprocessing Market could continue growing steadily.

The continuous bioprocessing market share from the research and development segment will register a notable CAGR from 2024 to 2032. Continuous bioprocessing offers numerous advantages over traditional batch processes, including enhanced process control, reduced manufacturing footprint, and faster development timelines. As biopharmaceutical companies seek to streamline their R&D efforts and accelerate the time-to-market for new therapies, the adoption of continuous bioprocessing is rapidly gaining traction. Its ability to facilitate continuous data generation, process optimization, and scale-up from small-scale experiments to commercial production makes it an indispensable tool in modern biopharmaceutical R&D endeavors. Thus, continuous bioprocessing is poised to reshape the landscape of biopharmaceutical innovation and development.

Asia Pacific continuous bioprocessing market will showcase a commendable CAGR from 2024 to 2032. Rapid industrialization, in line with the expanding biopharmaceutical sector in countries like China, India, and South Korea, is driving the demand for advanced bioprocessing technologies. Moreover, increasing investments in research and development, alongside government initiatives promoting biotechnology, are fueling market growth. The Asia-Pacific region's strategic importance as a manufacturing hub for pharmaceuticals and biologics further boosts demand for continuous bioprocessing solutions. As a result, the Asia-Pacific market is emerging as a significant contributor to the global expansion of the Continuous Bioprocessing Market.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & calculations
  • 1.3 Data validation
  • 1.4 Data collection
  • 1.5 Forecast parameters
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing demand for biopharmaceuticals
      • 3.2.1.2 Growing adoption of continuous bioprocessing among CMOs and CDMOs
      • 3.2.1.3 Advancements in continuous bioprocessing technologies
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High equipment cost
      • 3.2.2.2 Stringent regulatory requirements
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
    • 3.5.1 Supplier power
    • 3.5.2 Buyer power
    • 3.5.3 Threat of new entrants
    • 3.5.4 Threat of substitutes
    • 3.5.5 Industry rivalry
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Instruments
    • 5.2.1 Chromatography systems
    • 5.2.2 Filtration systems and devices
    • 5.2.3 Bioreactors
    • 5.2.4 Other instruments
  • 5.3 Consumables
    • 5.3.1 Cell culture media & buffers
    • 5.3.2 Reagents

Chapter 6 Market Estimates and Forecast, By Scale of Operation, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Commercial
  • 6.3 Research and development

Chapter 7 Market Estimates and Forecast, By Process, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Downstream bioprocess
  • 7.3 Upstream bioprocess

Chapter 8 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Monoclonal antibodies
  • 8.3 Vaccines
  • 8.4 Cell and gene therapy
  • 8.5 Other applications

Chapter 9 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Pharmaceutical and biotechnology companies
  • 9.3 CMOs and CROs
  • 9.4 Research and academic institutes

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 3M Company
  • 11.2 Bionet
  • 11.3 Danaher Corporation (Pall Corporation)
  • 11.4 Eppendorf SE
  • 11.5 FUJIFILM HOLDINGS CORPORATION
  • 11.6 Merck KGaA
  • 11.7 Repligen Corporation
  • 11.8 Sartorius AG
  • 11.9 Thermo Fisher Scientific Inc.
  • 11.10 WuXi Biologics